ArticleNature biotechnology2021
Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4
Article in Nature biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells.Nature protocols · 2026Review
- Article
- Legacy of the discovery of the T-cell receptor: 40 years of shaping basic immunology and translational work to develop novel therapies.Cellular & molecular immunology · 2024Article
- YTHDF2 favors protumoral macrophage polarization and implies poor survival outcomes in triple negative breast cancer.iScience · 2024Article
- Preservation of naive-phenotype CD4+ T cells after vaccination contributes to durable immunity.JCI insight · 2024Article
- Differentiation marker-negative CD4bioRxiv : the preprint server for biology · 2024Article
- Antigen-specific and cross-reactive T cells in protection and disease.Immunological reviews · 2023Review
- A universal MHCII technology platform to characterize antigen-specific CD4Cell reports methods · 2023Article
- Genetically engineered CD80-pMHC-harboring extracellular vesicles for antigen-specific CD4Frontiers in bioengineering and biotechnology · 2023Article
- Nanoparticle-based modulation of CD4Nature communications · 2022Article
- In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles.Science advances · 2022Article
- HTLV-1 infection promotes excessive T cell activation and transformation into adult T cell leukemia/lymphoma.The Journal of clinical investigation · 2021Article
- Recent advances in cancer immunotherapy.Discover oncology · 2021Review
- Mechanistic and Biomarker Studies to Demonstrate Immune Tolerance in Multiple Sclerosis.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide-major histocompatibility complex (pMHC) multimers enable the detection of antigen-specific T cells in studies ranging from vaccine efficacy to cancer immunotherapy. However, this technology is unreliable when applied to pMHC class II for the detection of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.